52 Views | 20 Downloads
Yury V. Kuzmichev, Email: yury.v.kuzmichev@emory.edu
Y.V.K. contributed to conceptualization, formal analysis, investigation, methodology, writing (original draft), and visualization. E.R.W. contributed to conceptualization, formal analysis, methodology, project administration, supervision, visualization, and writing (original draft). D.A.K. contributed to conceptualization, formal analysis, funding acquisition, methodology, project administration, supervision, and writing (original draft). C.L.-S. contributed to data curation, formal analysis, and methodology. A.W., M.J.B., and A.M. performed single-genome sequencing analysis and visualization. R.G.P. contributed to funding acquisition, methodology, and project administration. M.S. and S.B. performed HIV-1 RNA quantification on the Panther system. N.A. and J.A. contributed to investigation and provided participant samples from RV130/514 trial. W.B. and S.T. contributed to investigation. S.T. performed total and integrated HIV DNA measurement. M.F.K. contributed to methodology and supervision. M.P.B. provided participant samples from RAVEN cohort. All authors contributed to the critical review and editing of the manuscript.
This work was supported with federal funds from the NIH/NIAID/DAIDS under contract HHSN272201500017C entitled “Quantitative Viral Outgrowth Assay (QVOA) Service Resource”-Dr. Betty Poon (COR). This work was further supported by intramural funds from NIH/NCI to Dr. Mary F. Kearney. Hologic provided reagents and support for HIV RNA viral load testing of the QVOA culture supernatants using the Aptima assay on the Panther platform. This work was supported with funds from the Bill and Melinda Gates Foundation award INV-008500 (to M.P.B.). The RV130 study was executed by the Infectious Disease Clinical Research Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed Services University of the Health Sciences (USUHS) through a cooperative agreement by the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). RV130 has been funded with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), under Inter-Agency Agreement Y1-AI-5072. RV514 study was supported through Military HIV Research Program. Furthermore, this work was supported by UM1AI164562, co-funded by National Heart, Lung and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute on Drug Abuse and the National Institute of Allergy and Infectious Diseases (to D.A.K. and Y.V.K.). We thank Drs. Betty Poon and Roger Miller for their intellectual input and discussions throughout this project. We are grateful to Krupa Subramanian, Christine Raney, Hayley P. Blankenship, Chunsheng Huang, and Jiayi Wei for technical expertise, and Ellen R. Nordgren and Rachel L. Jarret for their support in providing clinical sample management.
The authors have declared that no competing interests exist. The views expressed are those of the authors and should not be construed to represent the positions of the Uniformed Services University, the Department of Defense, US Army, or the United States Government. The investigators have adhered to the policies for protection of human subjects as prescribed in Army Regulation 70-25.
© The Author(s) 2023